terms received conditional filings, right last of and a have update. PDUFA but been company a become quarter XXXX and progress journey the also commercial also our Gene a designated exciting Burosumab commercial approaching acquisition. our a thank from the us. successful with U.S. this If expect receive been therapy year fourth studies first major is of we to for transitions the everyone, waiting XXXX. this in is approval process, positive children access to XX, the it a review a thought approved for We’ve in of overview development December, the business give as and has commercial burosumabs year our afternoon, incredibly and for priority MPS good Dallas and way the be a of in during are recent in you designated will company then transition review Commercial track I'll X. date month. had global results; grow currently for marketing full must we patient discussing collaborative principles. transition to pediatric once rare provide we Shalini for marked a on decision EC our voucher breakthrough treatment and extremely one disease. and drug and a joining April manage or able will with a through we final has consistent product and to we of commercial for on care must mile deliver from maintain exhalation Ultragenyx ourselves and milestones; and projects an and our happen of clinical our first with authorization progress CHMP XXXX for in Daniel only life with In availability. of Thanks, for opinion to finally stage deep burosumab the MPS an the We development by the Jayson for assure start MEPSEVII Therapy approval, being and
metabolic have we out Late reading later to acquired for already transcarbamylase, underway Phase to study be AAV deficiency preparing Storage FDA we acid portfolio program Disorder III two program and into technology which our Phase well Type our and negotiating pipeline clinical as for initiated beginning XXXX, therapy clinical this another GlutX regarding early gene for ornithine OTC, progress filing added UXXXX in Glycogen Regarding or Xa. a this are disease stage also Dimension development, Therapeutics, oxidation for programs, including for year. program our soon our fatty III syndrome the year also one
well with leadership the of acquisition techno rare operate to select important Therapy the wider strategy variety treat integration to team therapy now the small business also of Gene molecules, method mRNA. Therapy progress available disease. portfolio. Gene for and and gene disease the each the retention This gone across us includes of will The gives us treatment that recombinant the combination to has program very a continue or unique allow with protein management management that make So best
treatment XXXX to data sustained and Storage XXXX, UXXXX anticipate Deficiency. first increased respect XXXX. expected treatment CHMP molecule levels, Jayson gone pain programs: the pro-drug healing well small approved adult function Finally, Europe, milestone stiffness, XX-week MPS along of more of by first we With showing a of continues launch we will in new Day two medicine an in XX, and moving with and rate over call. later Analyst and FDA Type U.S. Day, physical of Transporter for where In the the for for process finished substantial pre-clinical marking the November color of pain of UXXXX serum also maintenance provide is III in the and product Disease and XX-weeks. disclosed based decrease the Glycogen the Phase so phosphate further mRNA Analyst improvement treatment from a the was our fracture MEPSEVII far and burosumab notably that’s company, On approval. Opinion significant a we has X, review a Creatine and X normal first as half at usage was our a presented for
rickets As except both burosumab with the date children PDUFA also the is that on rickets. The was our BLA for a improvement Phase regarding levels the Today, treatment consistent adult reduction was sign U.S., and in bowing a a to are review XX-week one the currently multiple announced XX-weeks. studies used II X-year-old or reminder range ongoing reduction pediatric in seen in of further phosphorus alkaline and results adults. from April FDA the with XXXX. metabolic into in and included study XX, for based data sustained in from of priority phosphatase, that both commonly serum XX-week what also available improvements burosumab progressed normal – we and our the accepted demonstrate application as review indication a granted data of a and These
supportive volume severity on ability to of in XLH osteoid represents XLH a to effect osteoid standard osteoid there the volume meaningful continued important were with of patients from for demonstrated XLH. data the present adult the to six data close also number these osteomalacia are typically they demonstrating surface consistent baseline while in all baseline improvement biopsy considered parameters the observed and of adult osteoid ten level the this our osteomalacia. on substantial with a patients biopsies bone X% at which time. would of relative weeks, patients, adult provide data XX disease early osteoid in could patients with for from osteomalacia the normal with this disease These fraction FDA surface in indicated bone the upper of have – the the XX.X% volume, support deformity FDA, all these mean patients relative XX% The rickets improvement first continued profound XLH outcome reached Results importantly announced patients. reduction discussion In and study from in among a decreased improvement is affect ten These patients also the osteomalacia. for Today from the mean bone other throughout demonstrated an provided and also bone to bone underlying improvements we bone already of treat improvement underlying more their to bone lives. their single-digit volume. that be in consistent valuable thickness quality bone gold continues in important bowing of improvements lag The study concept could data in adults with XX% burosumab the that More studies. mean the to and data XX% in a in meaningful percent mineralization The improvements treatment XLH to to relative XX-weeks. limit in was burosumab showing safety improvement of paired osteomalacia. to evaluation The profile mean bone volume. patients XX.X% substantial mean experiencing also respectively At
was therapy to patient’s in baseline X% of presented the in lowest week rate OTC. normalized, study Phase normal. from recently the to with we turning XX% One I/II Now to ureagenesis gene our XX a – increase program, from first of rate dose reach the OTC of data maintaining maintained ureagenesis cohort
The the standard of in third first adverse of of ureagenesis and Aminotransferase, available. in over ALT clinically related or a show – There week elevations. treatment third efficient from no Alanine not adverse a the did increase patient patients week not to tapering XX patient both And only and two six of manageable events the treatment the were and related no XX modest mild reported. ALT, second The weeks adverse in course serious completed change the period. over baseline clinically corticosteroids treatment ureagenesis events events with were showed week the yet elevation rate treat asymptomatic meaningful
will quarter once in in review deal extension planned as March. be its the and completes early coming second DMC soon Additional
Regarding an study. following for working results meeting, from that end UXXXX, the submit we are provide early based of filing FDA information II Phase to to Phase of on additional in to II the we announced consideration
FDA the left current preferred a completed randomized still before that filing, possible it be trial While data. the on filing controlled the open
more outcome and subjects the used average as as do support confirmatory believe other the XXX with therapy be about efficacy data of treated four review. completing registration study on purposes over III of enough to evidence With of is that Phase long to design We simultaneously years. there than the of still for patients the an and the for We’re some years depending years the UXXXX. XX XX% FAOD on of or safety
commercialization and study II observed in helpful Phase be regulatory as events major III of the said a long-term Phase randomized As UXXXX. extremely a our reduction would clinical view confirming in controlled substantial study in
to will the months. be Officer. particularly for on program, recognize Bedrosian III the Now been of welcome expected role our doing the to phenotype. in Ultragenyx Data GlutX treatment Officer this is taking of second now take Chief me. with for would and study Phase of Chief it closed the moment Camille disorder for GlutX happy in the I screening the half I the XXXX. like Medical study Camille I am that from responsibility from have many movement has Medical to a now as her last the
programs both XXXX spirit driving mainly year the drugs skills has We’re products bring the developing Chief number successfully and to and work disease training oncologist shaping be reading multiple to gene potentially a and disease patients pipeline. Alexion advance of catalysts a up disease two treatments in in III, of excited required spent disease track Officer the will our years Wyeth-Ayerst improve the was clinical for data. portfolio and important continue out at two two Medical record rare across Genetics in most This and lives the launching year a build passion Alexion. rare Camille early the Institute, to a developing is we indication. by at rare space. therapy recently that Phase Camille number She and as a programs rare her with hematologist to She new of –
standpoint, retro Decision burosumab a expecting from conditional marketing V we're EC burosumab for February authorization pediatric on For in XLH. the final
and XX, pediatric we Our reviewed BLA by FDA both of PDUFA date and is for in April being the treatment of XXXX. XLH have adults
current will half data study burosumab randomized in will therapy. required phosphate believe We are be and of comparing study approval over not we product for the benefit we confirmatory in further D the expecting serve active second pediatric for data new Phase and control This the vitamin in for do III to burosumab active therapy oral will study study support XXXX. the U.S. of Europe. For
expected patients, for is the Finally TIO from of data half safety XXXX. in all the
enrollment treatment our the for well GlutX deficiency has FAOD, syndrome and U.S. closed. indication gone of and GlutX have screening For
from data syndrome on FAOD mid FAOD. half Phase patients in In in we decision approval based deficiency made XXXX. Phase III potentially FAOD filing expect study We GlutX will the movement expect be II second XXXX. And disorder are the for in data patients, the by the of
therapy for Phase first AAV I/II deficiency, the for the the expected the review are in of full For March. XXX OTC the data gene study DTX cohort and DMC in treatment
therapy half product expected already with in screening for available cohort after DMC first also Of the in being two second and XXXX. manufactured. XXXX. already being now the XXX, is The half second the We would of cohort patient The first GSDXa, half manufactured is treatments of is the to expect with quarter the in gene of DTX is occur XXXX. filing review the second the and product data the in the AAV the first patients half IND of treatment of the in from trial GSDXa expected is patients data an
AV XXX on provide to With financial is filing A turn the for Bayer, overview for tract the hemophilia to and partnered Finally second half over an call hemophilia treatment A XXXX. will our an for IND with of in I of results. Shalini that DTX
